Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Murphy, Philip M  [Clear All Filters]
2023
Anginot A, Nguyen J, Nader ZAbou, Rondeau V, Bonaud A, Kalogeraki M, Boutin A, Lemos JP, Bisio V, Koenen J, et al. WHIM Syndrome-linked CXCR4 mutations drive osteoporosis. Nat Commun. 2023;14(1):2058.
2021
Li W, Liu C, Burns N, Hayashi J, Yoshida A, Sajja A, González-Hernández S, Gao J-L, Murphy PM, Kubota Y, et al. Alterations in the spatiotemporal expression of the chemokine receptor CXCR4 in endothelial cells cause failure of hierarchical vascular branching. Dev Biol. 2021.
2015
Li Z, Xu X, Weiss ID, Jacobson O, Murphy PM. Pre-treatment of Allogeneic Bone Marrow Recipients with the CXCR4 Antagonist AMD3100 Transiently Enhances Hematopoietic Chimerism without Promoting Donor-specific Skin Allograft Tolerance. Transpl Immunol. 2015.
2014
Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, Horuk R, Sparre-Ulrich AHovard, Locati M, Luster AD, et al. International Union of Pharmacology. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine Receptors. Pharmacol Rev. 2014;66(1):1-79.
McDermott DH, Liu Q, Velez D, Lopez L, Anaya-O'Brien S, Ulrick J, Kwatemaa N, Starling J, Fleisher TA, Priel DALong, et al. A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood. 2014.